A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
| 対象疾患 | Non-Small Cell Lung Cancer |
|---|---|
| 相 | 第2相 |
| スポンサー | AstraZeneca |
| ステータス | 実施中（募集終了） |
| 参加者数 | 30 名 |
| 介入（薬剤） | Osimertinib + Savolitinib, Savolitinib + Placebo |
| 開始日 | 2020年9月28日 |
| 完了日 | 2022年12月21日 |
| 結果公開日 | 2024年9月24日 |
概要
This study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-small cell lung cancer who have progressed following treatment with osimertinib.
Objective Response Rate (ORR)
| Savolitinib Plus Osimertinib | 57.1 Percentage of participants |
|---|---|
| Savolitinib Plus Placebo | 12.5 Percentage of participants |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)
- Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Pos — National Cancer Institute (NCI)
- Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage I — National Cancer Institute (NCI)
- Premedication to Reduce Amivantamab Associated Infusion Related Reactions — Janssen Research & Development, LLC
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab — Janssen Research & Development, LLC